In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Metra Biosystems

This article was originally published in The Gray Sheet

Executive Summary

Metra Biosystems: Gains 510(k) clearance for the use of the Pyrilinks-D bone resorption immunoassay to monitor anti-resorptive therapies, including Merck's Fosamax (alendronate), in the treatment and prevention of osteoporosis. The clearance is based upon a randomized, placebo-controlled clinical trial conducted by Merck to demonstrate the efficacy of alendronate in postmenopausal women diagnosed with osteoporosis. First cleared by the FDA in December 1995 for measuring bone resorption, Pyrilinks-D was used in the Merck trial to compare Dpd levels in subjects who received either alendronate and a calcium supplement or a calcium supplement alone...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts